Palliative and supportive care
- The Use of Complementary Medicines is Relatively High Among Patients in Phase III Cancer Trials
- The EPIPHANY Index Assesses Risk of Short-Term Serious Complications in Patients with Cancer and Pulmonary Embolism
- EMA Grants a Positive Opinion for LysaKare (Arginine/lysine)
- FDA Approves Dalteparin Sodium for Venous Thromboembolism in Paediatric Patients
- EMA Recommends Granting a Marketing Authorisation for New Biosimilar Pegfilgrastim
- De-escalation of Commonly Used Bone-Treating Agents Is A Reasonable Treatment Option for Patients with Bone Metastases from Breast Cancer
- Withdrawal of the EU Marketing Authorisation Applications for Cavoley and Efgratin
- Anticancer Vaccines Gain new Lease of Life with Personalisation Techniques [ESMO Press Release]
- Misconceptions about Opioids Affect Pain Control Among Cancer Patients: a Malaysian Survey [ESMO Asia 2018 Press Release]
- Multi-strain probiotic reduces chemotherapy-induced diarrhoea [ESMO 2018 Press Release]
- Regular exercise should be part of cancer care for all patients [ESMO 2018 Press Release]
- Trust in non-conventional therapies by cancer patients not matched with proper awareness about their risks [ESMO 2018 Press Release]
- EMA Recommends Extension of Indications for Epoetin Alfa (Abseamed, Binocrit and Epoetin alfa Hexal)
- EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim
- Management of Cancer Pain in Adult Patients: ESMO Clinical Practice Guidelines
- Diagnosis, Assessment and Management of Constipation in Advanced Cancer: ESMO Clinical Practice Guidelines
- Delirium in Adult Cancer Patients: ESMO Clinical Practice Guidelines
- FDA Approves Avatrombopag for Thrombocytopenia in Adults with Chronic Liver Disease
- Diarrhoea in Adult Cancer Patients: ESMO Clinical Practice Guidelines
- FDA Approves Fulphila to Decrease the Risk of Infection During Cancer Treatment
- ASCO 2018: Alternative Therapies Improve Insomnia Symptoms in Cancer Survivors
- NICE Issues Interventional Procedures Guidance on Low-Level Laser Therapy
- FDA Approves Retacrit as a Biosimilar to Epogen/Procrit
- Withdrawal of Application for a Change to the Marketing Authorisation for Aranesp (Darbepoetin Alfa)
- EMA Recommends Extension of Therapeutic Indications for Fosaprepitant